Sugi Predict

Sugi Predict / Compounds / SCHEMBL2948783

SCHEMBL2948783

SCHEMBL2948783

CCC(CO)Nc1ccc2ncc(-c3cccc(OC)c3)n2n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ FYN P06241 5/20 1.00
▸ DYRK1A Q13627 15/20 0.76
▸ DYRK2 Q92630 15/20 0.76
▸ DYRK1B Q9Y463 15/20 0.76
▸ DYRK3 O43781 13/20 0.76
▸ CDK5 Q00535 11/20 0.76
▸ CDK5R1 Q15078 11/20 0.76
▸ CCNT1 O60563 10/20 0.76
▸ CDK9 P50750 10/20 0.76
▸ CCNA2 P20248 9/20 0.76
▸ CDK2 P24941 9/20 0.76
▸ CLK1 P49759 1/20 0.68
▸ CLK2 P49760 1/20 0.68
▸ CLK3 P49761 1/20 0.68
▸ CLK4 Q9HAZ1 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL102236 0.88 FYN (0.79) FYNDYRK1ADYRK2DYRK1BDYRK3
SCHEMBL102764 0.88 FYN (0.79) FYNDYRK1ADYRK2DYRK1BDYRK3
SCHEMBL2942611 0.88 FYN (0.81) FYNDYRK1ADYRK2DYRK1BDYRK3
SCHEMBL2942425 0.87 FYN (1.00) FYNDYRK1ADYRK2DYRK1BDYRK3
SCHEMBL102233 0.86 DYRK1A (1.00) FYNDYRK1ADYRK2DYRK1BDYRK3
SCHEMBL102235 0.85 DYRK1A (1.00) FYNDYRK1ADYRK2DYRK1BDYRK3
SCHEMBL2950347 0.85 DYRK1A (0.79) FYNDYRK1ADYRK2DYRK1BDYRK3
SCHEMBL102656 0.85 DYRK1A (0.79) FYNDYRK1ADYRK2DYRK1BDYRK3
SCHEMBL2943853 0.84 FYN (0.81) FYNDYRK1ADYRK2DYRK1BDYRK3
SCHEMBL102951 0.84 DYRK1A (0.76) FYNDYRK1ADYRK2DYRK1BDYRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180250297-A1 Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors Pathways Neuro Pharma, Inc. 2018-09-06 — — US claimed
EP-3347462-A1 METHODS, COMPOSITIONS, AND USES OF NOVEL FYN KINASE INHIBITORS Lau, Warren C. (US) 2018-07-18 — — EP claimed
WO-2017044623-A1 METHODS, COMPOSITIONS, AND USES OF NOVEL FYN KINASE INHIBITORS LAU WARREN C (US) 2017-03-16 — — WO claimed
US-20240041868-A1 Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors Pathways Neuro Pharma, Inc. 2024-02-08 — — US disclosed
US-11701353-B2 Methods, compositions, and uses of novel FYN kinase inhibitors Pathways Neuro Pharma, Inc. (US) 2023-07-18 — — US disclosed
US-11701353-B2 Methods, compositions, and uses of novel FYN kinase inhibitors Pathways Neuro Pharma, Inc. (US) 2023-07-18 — — US disclosed
US-11701353-B2 Methods, compositions, and uses of novel FYN kinase inhibitors Pathways Neuro Pharma, Inc. (US) 2023-07-18 — — US disclosed
US-20210030753-A1 Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors Pathways Neuro Pharma, Inc. 2021-02-04 — — US disclosed
US-10688093-B2 Methods, compositions, and uses of novel Fyn kinase inhibitors Pathways Neuro Pharma, Inc. 2020-06-23 — — US disclosed
US-10688093-B2 Methods, compositions, and uses of novel Fyn kinase inhibitors Pathways Neuro Pharma, Inc. 2020-06-23 — — US disclosed
US-20180250297-A1 Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors Pathways Neuro Pharma, Inc. 2018-09-06 — — US disclosed
US-7750000-B2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG (DE) 2010-07-06 — — US disclosed
US-7750000-B2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG (DE) 2010-07-06 — — US disclosed
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-04-26 — — US disclosed
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-04-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240041868-A1 Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors FYN, LCK, PTK2B FYN 1/4885DYRK1A 228/4885DYRK2 84/4885
US-20180250297-A1 Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors FYN, LCK, PTK2B FYN 1/4885DYRK1A 228/4885DYRK2 84/4885
US-11701353-B2 Methods, compositions, and uses of novel FYN kinase inhibitors FYN, LCK, PTK2B FYN 1/4885DYRK1A 228/4885DYRK2 84/4885
US-10688093-B2 Methods, compositions, and uses of novel Fyn kinase inhibitors FYN, LCK, PTK2B FYN 1/4885DYRK1A 228/4885DYRK2 84/4885
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments MAP4K2, MAP3K1, MAP3K2 FYN 421/4885DYRK1A 461/4885DYRK2 336/4885
US-20210030753-A1 Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors FYN, LCK, PTK2B FYN 1/4885DYRK1A 228/4885DYRK2 84/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.